When it comes to handing over your precious research samples to a contract research organization (CRO), how do you know you are outsourcing to the right company? Larger CROs seem to offer every type of analysis available, from genomics to histopathology. But specialty CROs may be a better option, especially if you need sophisticated techniques and data analysis.
Flow Cytometry Blog
Make Your Decision With These 5 Questions
You have just gotten approval to start a big phase 1 clinical trial and 172 precious blood samples are about to come through your door in about two months. What do you do? Do you clone yourself and your outstanding flow cytometry skills? Do you consider skipping sleep for a few weeks? Do you panic? Perhaps, you should consider outsourcing your flow cytometry analysis ...
Have you ever started a flow cytometry run and you cannot see any cells? This can be an alarming feeling, but some straightforward troubleshooting can usually help you find your missing cells. Check out these three questions to tackle common issues associated with disappearing cells.
Unlike solid tumors, blood cancers such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) may be monitored by measuring the presence and frequency of cancerous blood cells in the peripheral blood or bone marrow. Minimal residual disease (MRD) assessment uses different techniques to measure the presence of malignant cells, even at low frequency, and has been used as a key prognostic for guiding treatment decisions in pediatric and adult leukemia patients and assigning patients into different MRD-based risk groups. 
Immunotherapeutic molecules currently being used in the clinic are powerful immune modulators, but their effectiveness can be inconsistent between patients. Clinicians and scientists use different assays to evaluate why immunotherapies fail in the clinic. The flow cytometry-based receptor occupancy (RO) assay is a critical tool for evaluating the effectiveness of immunotherapies in the clinic. Here are three features of flow cytometry-based RO assays that give them clinical value.